Edward Tobinick

Edward Lewis Tobinick is an American physician who is board-certified in internal medicine and dermatology and claims to have developed new methods of treating neurological disorders. Dr. Tobinick is co-author of the recent case report alleging rapid clinical improvement in a patient with Alzheimer's disease following perispinal administration of etanercept which has been received with considerable interest. Wyeth in collaboration with the University of Southampton has, as of January 2011, begun enrollment into a randomized, placebo-controlled clinical trial of etanercept for patients with Alzheimer's disease. Also being trialed currently, in a multi-center study, is the use of epidural etanercept for sciatica (U.S. patent 6,419,944 issued to Tobinick July 2002), for which favorable randomized, placebo-controlled clinical data from Walter Reed Army Medical Center were published in 2009 (Anesthesiology. 2009 May;110(5):1116-26). Etanercept (Enbrel) is a potent inhibitor of a cytokine called TNF (Tumor necrosis factor alpha).

Tobinick is also lead author of a December 2012 study that provided evidence that excess TNF contributes to chronic neurological, neuropsychiatric and clinical impairment after stroke and Traumatic brain injury (TBI) and that perispinal etanercept was therapeutically useful for these indications. In May 2013 a group of Canadian physicians announced the initiation of a clinical trial of etanercept for subarachnoid brain hemorrhage. In June 2013 two independent studies were published that suggest that TNF may play an important role in the neuropathology following stroke and TBI: 1. A study from the UK that provided evidence that one's TNF genetic makeup has an impact on clinical outcome after TBI; and 2. A basic science study from Stanford that provided data that suggests that TNF inhibition may reduce brain damage after acute neurological insult. Additional studies in 2013 provided specific relevant evidence.

Tobinick has been issued patents for methods of perispinal administration, of certain recombinant DNA-derived (biologic) therapeutics including the TNF receptor fusion protein etanercept, for the treatment of certain neurologic disorders with widespread unmet medical need, including Alzheimer's disease; pain due to cancer metastasis to bone; severe, intractable, intervertebral disc-related pain and radiculopathy (including sciatica); and myasthenia gravis. In addition, he originated the concept of the potential utility of etanercept, alone or in combination with oseltamivir for treatment of influenza (U.S. patent 6,419,934, filed September 5, 2000 [1]). For these novel treatment methods he has been issued multiple U.S. patents, including 6,015,557 (Tumor necrosis factor antagonists for the treatment of neurological disorders) [2]; 6,177,077 [3]; 6,419,934 [4]; and 6,982,089 [5]. In general, his concepts represent emerging therapeutic strategies supported by small pilot studies and expert reviews. (see Publications and References).

Aetna has published a Clinical Policy Bulletin which concludes that the use of etanercept to treat stroke, back pain, and traumatic brain injury should be considered experimental and investigational.

Tobinick earned his M.D. from the UC San Diego School of Medicine in 1977.

Publications

• Tobinick E, Kim N, Reyzin G, Rodriguez-Romanacce H, DePuy V. (2012). "Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept". CNS Drugs. 26 (12): 1051–70. doi:10.1007/s40263-012-0013-2. PMID 23100196.{{cite journal}}: CS1 maint: multiple names: authors list (link)
• Tobinick E (2012). "Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer's disease". Current Alzheimer Research. 9 (1): 99–109. doi:10.2174/156720512799015073. PMID 22191562.
• Tobinick E (2011). "Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases". CNS Drugs. 25 (2): 145–155. doi:10.2165/11588400-000000000-00000. PMID 21254790.
• Tobinick E (2010). "Perispinal etanercept: a new therapeutic paradigm in neurology". Expert Review of Neurotherapeutics. 10 (6): 985–1002. doi:10.1586/ern.10.52. PMID 20518613.
• Tobinick E (2009). "Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence". CNS Drugs. 23 (9): 713–25. doi:10.2165/11310810-000000000-00000. PMID 19689163.
• Tobinick E, Chen K, Chen X. (2009). "Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging". BMC Res Notes. 2: 28. doi:10.1186/1756-0500-2-28. PMC 2651903. PMID 19284700.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
• Tobinick Edward (2009). "Perispinal etanercept for neuroinflammatory disorders". Drug Discovery Today. 14 (3–4): 168–77. doi:10.1016/j.drudis.2008.10.005. PMID 19027875.
• Tobinick Edward (2008). "Perispinal Etanercept Produces Rapid Improvement in Primary Progressive Aphasia: Identification of a Novel, Rapidly Reversible TNF-Mediated Pathophysiologic Mechanism". Medscape J Med. 10 (6): 135. PMC 2491668. PMID 18679537.
• Tobinick EL, Gross H (2008). "Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease". BMC Neurology. 8: 27. doi:10.1186/1471-2377-8-27. PMC 2500042. PMID 18644112.{{cite journal}}: CS1 maint: unflagged free DOI (link)
• Tobinick E, Gross H. (2008). "Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration". Journal of Neuroinflammation. 5 (2): 2. doi:10.1186/1742-2094-5-2. PMC 2211476. PMID 18184433.{{cite journal}}: CS1 maint: unflagged free DOI (link)
• Tobinick E (2007). "Perispinal etanercept for treatment of Alzheimer's disease". Current Alzheimer Research. 4 (5): 550–2. doi:10.2174/156720507783018217. PMID 18220520.
• Tobinick E, Gross H, Weinberger A, Cohen H. (2006). "TNF-alpha Modulation for Treatment of Alzheimer's Disease: A 6-Month Pilot Study". Medscape General Medicine. 8 (2): 25f. PMC 1785182. PMID 16926764.{{cite journal}}: CS1 maint: multiple names: authors list (link)
• Tobinick E.; Vega, CP (2006). "The Cerebrospinal Venous System: Anatomy, Physiology, and Clinical Implications". Medscape General Medicine. 8 (1): 53f. PMID 16915183.
• Tobinick E, Davoodifar S. (2004). "Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients". Curr Med Res Opin. 20 (7): 1075–85. doi:10.1185/030079903125004286. PMID 15265252.
• Tobinick E.; Britschgi-Davoodifar, S (2003). "Perispinal TNF-alpha inhibition for discogenic pain" (PDF). Swiss Med Wkly. 133 (11–12): 170–177. PMID 12715286.
• Tobinick, E (2003). "Targeted etanercept for discogenic neck pain: Uncontrolled, open-label results in two adults". Clinical Therapeutics. 25 (4): 1211–8. doi:10.1016/S0149-2918(03)80077-2. PMID 12809967.
• Tobinick E. (2003 (August)). "Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports". Clinical Therapeutics. 25 (8): 2279–88. doi:10.1016/S0149-2918(03)80219-9. PMID 14512134. {{cite journal}}: Check date values in: |year= (help)
• Tobinick E. (2004). "TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection". Curr Med Res Opin. 20 (1): 39–40. doi:10.1185/030079903125002757. PMID 14741070.
• Tobinick, Edward (1998). Skin Surgery: A Practical Guide. St. Louis: Mosby. ISBN 0-8151-7362-8. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

References

• Rosenberg P. (2006). "Editorial: Cytokine inhibition for treatment of Alzheimer's Disease". MedGenMed Neurology & Neurosurgery. 8 (2): 1. link

External links

• Edward Tobinick
• Institute for Neurological Research, a private medical group, inc.